Universitatea *Titu Maiorescu* din Bucureşti
Facultatea de Medicină
Departamentul Disciplinelor Medico-Chirurgicale şi Profilactice
Concurs pentru ocuparea postului de **ASISTENT UNIVERSITAR**, poziţia **230**
Disciplinele postului: **Primul ajutor medical; Medicină de urgență; Urgențe medicale și prim ajutor medical; Măsuri de prim ajutor**
Domeniul MEDICINĂ
Post publicat în Monitorul Oficial al României nr. 371, Partea a III-a, din 27 noiembrie 2025

LISTA DE LUCRĂRI[1]
a candidatului RADU DANIEL

1. Lista celor maximum 10 lucrări considerate de candidat a fi cele mai relevante pentru realizările profesionale proprii, care sunt incluse în format electronic în dosar şi care se pot regăsi şi în celelalte categorii de lucrări menţionate mai jos (cu referințe bibliografice complete):

R1. Impact of risk factors on the evolution of severe acute pancreatitis. Journal of Mind and Medical Sciences. I S S N : 2 3 9 2 - 7 6 7 4. Published: April 25, 2023

References

1. Roberts SE, Akbari A, Thorne K, Atkinson M, Evans PA. The incidence of acute pancreatitis: impact of social deprivation, alcohol consumption, seasonal and demographic factors. Aliment Pharmacol Ther. 2013; 38(5):539-548. doi:10.1111/apt.12408
2. Kumar RB, Karim T, Jain A, Arora S, Katiyar VK, Patel G. Role of Serum Interleukin-6 and C-reactive Protein in Early Prediction of Severe Acute Pancreatitis. J West Afr Coll Surg. 2022;12(4):20-26. doi:10.4103/jwas.jwas_186_22
3. Andersson R, Eckerwall G, Haraldsen P. Novel Strategies for the Management of Severe Acute Pancreatitis. In: Vincent, JL. (eds) Yearbook of Intensive Care and Emergency Medicine 2000. Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK,volume 2000), pp. 379–389. Springer, Berlin, Heidelberg. doi: 10.1007/978-3-662-13455-9_33
4. Doctor N, Agarwal P, Gandhi V. Management of severe acute pancreatitis. Indian J Surg. 2012;74(1):40-46. doi:10.1007/s12262-011-0384-5
5. Szakács Z, Gede N, Pécsi D, et al. Aging and Comorbidities in Acute Pancreatitis II.: A Cohort-Analysis of 1203 Prospectively Collected Cases. Front Physiol. 2019;9:1776. doi:10.3389/fphys.2018.01776
6. Ranson JH. Diagnostic standards for acute pancreatitis. World J Surg. 1997;21(2):136-142. doi: 10.1007/s002689900205
7. Larvin M, McMahon MJ. APACHE-II score for assessment and monitoring of acute pancreatitis. Lancet. 1989;2(8656):201-205. doi:10.1016/s0140-6736(89)90381-4
8. Wu BU, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. Gut.

[1] **Se prezintă obligatoriu şi în format PDF, obținut prin *conversie* a fișierului Word sau Excel, cu semnătura în clar, fără semnătura olografă (nu scanat).**

2008;57(12):1698-1703. doi:10.1136/gut.2008.152702
9. Savu C, Melinte A, Posea R, et al. Pleural Solitary Fibrous Tumors-A Retrospective Study on 45 Patients. Medicina (Kaunas). 2020;56(4):185. Published 2020 Apr 16. doi:10.3390/medicina56040185
10.Faur M, Dumitrescu D, Sabau D, Tanasescu C, Cretu D, Tanasescu D, Constantin VD, Mohor C. Clinical and biological factors with prognostic value in acute pancreatitis. J Mind Med Sci. 2022;9(2):310-317. doi: 10.22543/2392-7674.1352
11. Working Group IAP/APA Acute Pancreatitis Guidelines. IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology. 2013;13(4 Suppl 2):e1-e15. doi:10.1016/j.pan.2013.07.063
12. Yadav D, Ng B, Saul M, Kennard ED. Relationship of serum pancreatic enzyme testing trends with the diagnosis of acute pancreatitis. Pancreas. 2011;40(3): 383-389. doi:10.1097/MPA.0b013e3182062970
13.Faur M, Moisin A, Sabau AD, Sabau D. The surgical management of pancreatic pseudocysts – outcomes on a group of seven patients. J Mind Med Sci. 2022;9(1): 168-174. doi:10.22543/7674.91.P168174
14. Nasri S, Guerrouj I, Abbou W, Aichouni N, Kamaoui I, Skiker I. Diaphragmatic hernia a rare cause of acute pancreatitis: Case report. Radiol Case Rep. 2021; 17(3):572-576. doi:10.1016/j.radcr.2021.11.042
15. Dumitrescu D, Savlovschi C, Borcan R, et al. Caz clinic--hernie diafragmatică voluminoasă--abdomen acut chirurgical: dificultăţi diagnostice şi terapeutice [Clinical case--voluminous diaphragmatic hernia-- surgically acute abdomen: diagnostic and therapeutical challenges]. Chirurgia (Bucur). 2011;106(5):657-660.
16.Serban D, Tribus LC, Vancea G, et al. Acute Mesenteric Ischemia in COVID-19 Patients. J Clin Med. 2021;11(1):200. Published 2021 Dec 30. doi:10.3390/jcm11010200
17. Dumnicka P, Maduzia D, Ceranowicz P, Olszanecki R, Drożdż R, Kuśnierz-Cabala B. The Interplay between Inflammation, Coagulation and Endothelial Injury in the Early Phase of Acute Pancreatitis: Clinical Implications. Int J Mol Sci. 2017;18(2):354. Published 2017 Feb 8. doi:10.3390/ijms18020354.
18. Ionescu M, Stoian AP, Rizzo M, et al. The Role of Endothelium in COVID-19. Int J Mol Sci. 2021;22(21): 11920. doi:10.3390/ijms222111920.
19. Dimcevici Poesina N, Bălălău C, et al. Testicular histopathological changes following sodium fluoride administration in mice. Rom J Morphol Embryol. 2013; 54(4):1019-1024.
20. Zgura A, Gales L, Bratila E, Mehedintu C, Haineala B, Barac RI, Popa AR, Buhas C, Berceanu C, Andreescu CV, Anghel R. Variation of the T Lymphocytes

According to Treatment in Breast Cancer. Rev Chim. 2019;70(5):1649-1654. doi:10.37358/RC.19.5.7186
21. Zhou Q, Tao X, Xia S, et al. T Lymphocytes: A Promising Immunotherapeutic Target for Pancreatitis and Pancreatic Cancer?. Front Oncol. 2020;10:382. Published 2020 Mar 24. doi:10.3389/fonc.2020.00382
22. Serban D, Papanas N, Dascalu AM, et al. Significance of Neutrophil to Lymphocyte Ratio (NLR) and Platelet Lymphocyte Ratio (PLR) in Diabetic Foot Ulcer and Potential New Therapeutic Targets [published online ahead of print, 2021 Nov 18]. Int J Low Extrem Wounds. 2021;15347346211057742. doi:10.1177/15347346211057742
23.Jeon TJ, Park JY. Clinical significance of the neutrophil-lymphocyte ratio as an early predictive marker for adverse outcomes in patients with acute pancreatitis. World J Gastroenterol. 2017;23(21): 3883-3889. doi:10.3748/wjg.v23.i21.3883

24. Halaseh SA, Kostalas M, Kopec C, Toubasi AA, Salem R. Neutrophil-to-Lymphocyte Ratio as an Early Predictor of Complication and Mortality Outcomes in Individuals With Acute Pancreatitis at a UK District General Hospital: A Retrospective Analysis. Cureus. 2022;14(9):e29782. Published 2022 Sep 30. doi:10.7759/cureus.29782
25.Frey C, Zhou H, Harvey D, White RH. Co-morbidity is a strong predictor of early death and multi-organ system failure among patients with acute pancreatitis. J Gastrointest Surg. 2007;11(6):733-742. doi: 10.1007/s11605-007-0164-5
26. Busnatu SS, Salmen T, Pana MA, et al. The Role of Fructose as a Cardiovascular Risk Factor: An Update. Metabolites. 2022;12(1):67. Published 2022 Jan 12. doi:10.3390/metabo12010067
27. Murata A, Ohtani M, Muramatsu K, Matsuda S. Influence of comorbidity on outcomes of older patients with acute pancreatitis based on a national administrative database. Hepatobiliary Pancreat Dis Int. 2015;14(4): 422-428. doi:10.1016/s1499-3872(15)60398-8
28. McNabb-Baltar J, Ravi P, Isabwe GA, et al. A population-based assessment of the burden of acute pancreatitis in the United States. Pancreas. 2014;43(5):687-691. doi:10.1097/MPA.0000000000000123
29. Vasilopoulos T, Kotwal A, Huisingh-Scheetz MJ, Waite LJ, McClintock MK, Dale W. Comorbidity and chronic conditions in the National Social Life, Health and Aging Project (NSHAP), Wave 2. J Gerontol B Psychol Sci Soc Sci. 2014;69 Suppl 2(Suppl 2):S154-S165. doi:10.1093/geronb/gbu025

30. Nikolic D, Banach M, Chianetta R, Luzzu LM, Pantea Stoian A, Diaconu CC, Citarrella R, Montalto G, Rizzo M. An overview of statin-induced myopathy and perspectives for the future. Expert Opin Drug Saf. 2020; 19(5):601-615. doi: 10.1080/14740338.2020.1747431
31. Mikó A, Farkas N, Garami A, et al. Preexisting Diabetes Elevates Risk of Local and Systemic Complications in Acute Pancreatitis: Systematic Review and Meta-analysis. Pancreas. 2018;47(8):917-923. doi:10.1097/MPA.0000000000001122
32.Serban D, Popa Cherecheanu A, Dascalu AM, et al. Hypervirulent Klebsiella pneumoniae Endogenous Endophthalmitis-A Global Emerging Disease. Life (Basel). 2021;11(7):676. Published 2021 Jul 10. doi:10.3390/life11070676
33. Graham BB, Keniston A, Gajic O, et al. Diabetes mellitus does not adversely affect outcomes from a critical illness. Crit Care Med. 2010;38(1):16-24. doi:10.1097/CCM.0b013e3181b9eaa5
34. Garg R, Chaudhuri A, Munschauer F, Dandona P. Hyperglycemia, insulin, and acute ischemic stroke: a mechanistic justification for a trial of insulin infusion therapy. Stroke. 2006;37(1):267-273. doi: 10.1161/01.STR.0000195175.29487.30
35.Sun Q, Li J, Gao F. New insights into insulin: The anti-inflammatory effect and its clinical relevance. World J Diabetes. 2014;5(2):89-96. doi:10.4239/wjd.v5.i2.89
36. Li XY, Wang XB, Liu XF, Li SG. Prevalence and risk factors of organ failure in patients with severe acute pancreatitis. World J Emerg Med. 2010;1(3):201-204.

R2. **Pathophysiological mechanisms and benefits of SGLT-2 inhibitors in a patient with cerebral artery aneurysm: A case report. Received December 12, 2024; Accepted March 3, 2025**
DOI: 10.3892/etm.2025.12862. EXPERIMENTAL AND THERAPEUTIC MEDICINE 29: 112, 2025 SPANDIDOS PUBLICATION.

References

1. Heerspink HJ, Perkins BA and Fitchett D: Sodium-glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular outcomes and kidney disease. Lancet 396: 1239-1253, 2020.
2. Mocco J, Ransom ER, Komotar RJ, Schmidt JM, Sciacca RR, Mayer SA and Connolly ES Jr: Preoperative prediction of long-term outcome in poor-grade aneurysmal subarachnoid hemorrhage. Neurosurgery 59: 529-538, 2006.
3. https://www.ninds.nih.gov/health-information/disorders/cerebral- aneurysms.
4. Wiebers DO, Whisnant JP, Huston J III, Meissner I, Brown RD Jr, Piepgras DG, Forbes GS, Thielen K, Nichols D, O'Fallon WM, et al: Unruptured intracranial aneurysms: Natural history, clinical outcome, and risks of surgical and endovascular treatment. Lancet 362: 103-110, 2003.

5. Pepin M, Schwarze U, Superti-Furga A and Byers PH: Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med 342: 673-680, 2000.
6. Kielty CM, Sherratt MJ and Shuttleworth CA: Elastic fibres. J Cell Sci 115: 2817-2828, 2002.
7. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H and Ye S: Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 105: 418-423, 1999.
8. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, Hashikata H, Matsuura N, Yamazaki S, Toyoda A, et al: Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 6: e22542, 2011.
9. American Diabetes Association Professional Practice Committee: 6. Glycemic targets: Standards of medical care in diabetes-2022. Diabetes Care 45 (Suppl 1): S83-S96, 2022.
10. Ganesh J and Viswanathan V: Management of diabetic hypertensives. Indian J Endocrinol Metab 15 (Suppl 4): S374-S379, 2011.
EXPERIMENTAL AND THERAPEUTIC MEDICINE 29: 112, 2025 7
11. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42: 2439–2454, 2021.
12. American Diabetes Association Professional Practice Committee: 10. Cardiovascular disease and risk management: Standards of care in diabetes-2024. Diabetes Care 47 (Suppl 1): S179-S218, 2024.
13. Chalouhi N, Jabbour P and Tjoumakaris SI: Cerebral aneurysms: Pathogenesis, diagnosis, and treatment. J Neurosurg 118: 845-856, 2013.
14. Karsdal MA, Krarup H, Sand JMB, Christensen PB, Gerstoft J, Leeming DJ, Weis N, Schaffalitzky de Muckadell OB and Krag A: Review article: the efficacy of biomarkers in chronic fibroproliferative diseases-early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 40: 233-249, 2014.
15. Li J, Liu S, Li W, Hu S, Xiong J, Shu X, Hu Q, Zheng Q and Song Z: Vascular smooth muscle cell apoptosis promotes transplant arteriosclerosis through inducing the production of SDF-1α. Am J Transplant 12: 2029-2043, 2012.
16. Chen B, Lu Y, Chen Y and Cheng J: The role of Nrf2 in oxidative stress-induced endothelial injuries. J Endocrinol 225: R83-R99, 2015.
17. Sanchez Corredera C, Tadepalli PS, Scaccia J, Sibia AS and Mayrovitz HN: Implications of long sleep duration on cardiovascular health: A systematic review. Cureus 17: e77738, 2025.
18. Neumiller JJ, Alicic RZ and Tuttle KR: Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. J Am Soc Nephrol 28: 2263-2274, 2017.
19. Vasilenko LA and Zotov VV: Digitalization of public administration in Russia: Risks, casuses, problems. Digit Sociol 3: 4-16, 2020 (In Russian).
20. Liu Z, Ren Z, Zhang J, Chuang CC, Kandaswamy E, Zhou T and Zuo L: Role of ROS and nutritional antioxidants in human diseases. Front Physiol 9: 477, 2018.

21. Dunn SR and St. John L: The impact of SGLT2 inhibitors on endothelial function and vascular health: A review. Vasc Pharmacol 117: 29-37, 2019.
22. Cherney DZ, Prestidge RL and Qiu W: Effects of sodium-glucose cotransporter 2 inhibitors on kidney function and proteinuria: A review of the mechanisms and clinical effects. Can J Diabetes 42: 278-283, 2018.
23. Amzolini AM, Forțofoiu MC, Alhija AB, Vladu IM, Clenciu D, Mitrea A, Forțofoiu M, Matei D, Diaconu M, Tudor MS and Micu ES: Triglyceride and glucose index as a screening tool for nonalcoholic liver disease in patients with metabolic syndrome. J Clin Med 11: 3043, 2022.
24. Amzolini AM, Forţofoiu MC, Barău Abu-Alhija A, Vladu IM, Clenciu D, Mitrea A, Forţofoiu M, Matei D, Enăchescu V, Predescu OI and Micu ES: Triglyceride and glucose index: A useful tool for non-alcoholic liver disease assessed by liver biopsy in patients with metabolic syndrome? Rom J Morphol Embryol 62: 475-480, 2021.
25. Yaribeygi H, Maleki M, Jamialahmadi T, Moallem SA and Sahebkar A: Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders. EXCLI J 22: 403-414, 2023.
26. Pawlos A, Broncel M, Woźniak E and Gorzelak-Pabiś P: Neuroprotective effect of SGLT2 inhibitors. Molecules 26: 7213, 2021.
27. Jin Z, Deng H, Xiong S and Gao L: Perspective of SGLT2i in the treatment of abdominal aortic aneurysms. J Cardiovasc Pharmacol 81: 241-247, 2023.
28. Liu Y, Wu M, Xu B and Kang L: Empagliflozin alleviates atherosclerosis progression by inhibiting inflammation and sympathetic activity in a normoglycemic mouse model. J Inflamm Res 14: 2277-2287, 2021.

R3.The Impact of Insulin Resistance on Lung Volume Through Right Ventricular Dysfunction in Diabetic Patients—Literature Review. 1 August 2025. Journal of Personalized Medicine. *J.Pers. Med.*2025, *15*(8), 336;https://doi.org/10.3390/jpm15080336

References

1. Goldstein, B.J. Insulin resistance as the core defect in type 2 diabetes mellitus. *Am. J. Cardiol.* 2002, *90*, 3G–10G. [Google Scholar] [CrossRef] [PubMed]
2. Szoke, E.; Gerich, J.E. Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *Compr. Ther.* 2005, *31*, 106–112. [Google Scholar] [CrossRef] [PubMed]
3. Groop, L. Pathogenesis of type 2 diabetes: The relative contribution of insulin resistance and impaired insulin secretion. *Int. J. Clin. Pract. Suppl.* 2000, *113*, 3–13. [Google Scholar] [PubMed]
4. Min, J.; Putt, M.E.; Yang, W.; Al-Naamani, N.; Bertoni, A.G.; Lima, J.A.C.; Barr, R.G.; Beussink-Nelson, L.; Shah, S.J.; Kawut, S.M.; et al. Insulin Resistance Is Associated with Right Ventricular Dysfunction. *Ann. Am. Thorac. Soc.* 2022, *19*, 562–571. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
5. Kang, Y.; Wang, S.; Huang, J.; Cai, L.; Keller, B.B. Right ventricular dysfunction and remodeling in diabetic cardiomyopathy. *Am. J. Physiol. Heart Circ. Physiol.* 2019, *316*, H113–H122. [Google Scholar] [CrossRef] [PubMed]
6. Zhang, G.; Shi, R.; Li, X.M.; Yan, W.F.; Xu, H.Y.; Li, Y.; Guo, Y.K.; Shi, K.; Yang, Z.G. Impact of diabetes mellitus on right ventricular dysfunction and ventricular

interdependence in hypertensive patients with heart failure with reduced ejection fraction assessed via 3.0 T cardiac MRI. *Cardiovasc. Diabetol.* 2024, *23*, 375. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
7. Schofield, J.D.; Liu, Y.; Rao-Balakrishna, P.; Malik, R.A.; Soran, H. Diabetes Dyslipidemia. *Diabetes Ther.* 2016, *7*, 203–219. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
8. Bale, B.F.; Doneen, A.L.; Leimgruber, P.P.; Vigerust, D.J. The critical issue linking lipids and inflammation: Clinical utility of stopping oxidative stress. *Front. Cardiovasc. Med.* 2022, *9*, 1042729. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
9. Fakhry, B.; Peterson, L.; Comhair, S.A.A.; Sharp, J.; Park, M.M.; Tang, W.H.W.; Neumann, D.R.; DiFilippo, F.P.; Farha, S.; Erzurum, S.C.; et al. Blood Cholesterol and Triglycerides Associate with Right Ventricular Function in Pulmonary Hypertension. *medRxiv* 2024. [Google Scholar] [CrossRef] [PubMed]
10. Howard, B.V. Insulin resistance and lipid metabolism. *Am. J. Cardiol.* 1999, *84*, 28J–32J. [Google Scholar] [CrossRef] [PubMed]
11. Ma, J.I.; Zern, E.K.; Parekh, J.K.; Owunna, N.; Jiang, N.; Wang, D.; Rambarat, P.K.; Pomerantsev, E.; Picard, M.H.; Ho, J.E. Obesity Modifies Clinical Outcomes of Right Ventricular Dysfunction. *Circ. Heart Fail.* 2023, *16*, e010524. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
12. Brittain, E.L.; Talati, M.; Fessel, J.P.; Zhu, H.; Penner, N.; Calcutt, M.W.; West, J.D.; Funke, M.; Lewis, G.D.; Gerszten, R.E.; et al. Fatty acid metabolic defects and right ventricular lipotoxicity in human pulmonary arterial hypertension. *Circulation* 2016, *133*, 1936–1944. [Google Scholar] [CrossRef]
13. Hemnes, A.R.; Luther, J.M.; Rhodes, C.J.; Burgess, J.P.; Carlson, J.; Fan, R.; Fessel, J.P.; Fortune, N.; Gerszten, R.E.; Halliday, S.J.; et al. Human PAH is characterized by a pattern of lipid-related insuli resistance. *JCI Insight* 2019, *4*, e123611. [Google Scholar] [CrossRef]
14. Kolb, T.M.; Hassoun, P.M. Right ventricular dysfunction in chronic lung disease. *Cardiol. Clin.* 2012, *30*, 243–256. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
15. Price, L.C.; Wort, S.J.; Finney, S.J.; Marino, P.S.; Brett, S.J. Pulmonary vascular and right ventricular dysfunction in adult critical care: Current and emerging options for management: A systematic literature review. *Crit. Care* 2010, *14*, R169. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
16. McDonagh, T.A.; Metra, M.; Adamo, M.; Gardner, R.S.; Baumbach, A.; Böhm, M.; Burri, H.; Butler, J.; Čelutkienė, J.; Chioncel, O.; et al. 2022 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur. Heart J.* 2022, *43*, 3618–3731. [Google Scholar]
17. Real, C.; Perez-Garcia, C.N.; Galan-Arriola, C.; Garcia-Lunar, I.; Garcia-Alvare, A. Right ventricular dysfunction: Pathophysiology, experimental models, evaluation, and treatment. *Cardiologia* 2024, *77*, 957–970. [Google Scholar] [CrossRef]
18. Prins, K.W.; Archer, S.L.; Pritzker, M.; Rose, L.; Weir, E.K.; Sharma, A.; Thenappan, T. Interleukin-6 is independently associated with right ventricular function in pulmonary arterial hypertension. *J. Heart Lung Transplant.* 2017, *37*, 376–384. [Google Scholar] [CrossRef]
19. Hemnes, A.R.; Celermajer, D.S.; D'Alto, M.; Haddad, F.; Hassoun, P.M.; Prins, K.W.; Naeije, R.; Noordegraaf, A.V. Pathophysiology of the right ventricle and its pulmonary vascular interaction. *Eur. Respir. J.* 2024, *64*, 2401321. [Google Scholar] [CrossRef]
20. Prisco, S.Z.; Hartweck, L.M.; Rose, L.; Lima, P.D.A.; Thenappan, T.; Archer, S.L.; Prins, K.W. Inflammatory glycoprotein 130 signaling links changes in microtubules and junctophilin-2 to altered mitochondrial metabolism and right ventricular contractility. *Circ. Heart Fail.* 2022, *15*, e008574. [Google Scholar] [CrossRef]

21. Boucherat, O.; Yokokawa, T.; Krishna, V.; Kalyana-Sundaram, S.; Martineau, S.; Breuils-Bonnet, S.; Azhar, N.; Bonilla, F.; Gutstein, D.; Potus, F.; et al. Identification of LTBP-2 as a plasma biomarker for right ventricular dysfunction in human pulmonary arterial hypertension. *Nat. Cardiovasc. Res.* 2022, *1*, 748–760. [Google Scholar] [CrossRef]
22. Khassafi, F.; Chelladurai, P.; Valasarajan, C.; Nayakanti, S.R.; Martineau, S.; Sommer, N.; Yokokawa, T.; Boucherat, O.; Kamal, A.; Kiely, D.G.; et al. Transcriptional profiling unveils molecular subgroups of adaptive and maladaptive right ventricular remodeling in pulmonary hypertension. *Nat. Cardiovasc. Res.* 2023, *2*, 917–936. [Google Scholar] [CrossRef] [PubMed]
23. Cubero Salazar, I.M.; Lancaster, A.C.; Jani, V.P.; Montovano, M.J.; Kauffman, M.; Weller, A.; Ambale-Venkatesh, B.; Zimmerman, S.L.; Simpson, C.E.; Kolb, T.M.; et al. Poor cardiac output reserve in pulmonary arterial hypertension is associated with right ventricular stiffness and impaired interventricular dependence. *Eur. Respir. J.* 2024, *64*, 2400420. [Google Scholar] [CrossRef]
24. Bianchi, V.E. Impact of Nutrition on Cardiovascular Function, Current Problems in Cardiology. *Curr. Probl. Cardiol.* 2020, *45*, 100391. [Google Scholar] [CrossRef]
25. Kurup, S.; Lin, C.H.; Herrero, P.; Sidhu, J.; Venugopal, V.; Waggoner, A.D.; Stein, R.I.; Eagon, J.C.; Klein, S.; Gropler, R.J.; et al. Abstract 1563: Weight Loss Improves Right Atrial and Ventricular Function and Metabolism in Obese Humans. *Circulation* 2009, *120* (Suppl. S18), S518. Available online: https://www.ahajournals.org/doi/abs/10.1161/circ.120.suppl_18.S518-a (accessed on 20 May 2025).
26. Patel, T. SGLT2 inhibitors reduce adverse renal and CV outcomes in patients with or without diabetes. *Ann. Intern. Med.* 2023, *176*, JC27. [Google Scholar] [CrossRef] [PubMed]
27. Marx, N.; Husain, M.; Lehrke, M.; Verma, S.; Sattar, N. GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. *Circulation* 2022, *146*, 1882–1894. [Google Scholar] [CrossRef] [PubMed]
28. Malhotra, A.; Grunstein, R.R.; Fietze, I.; Weaver, T.E.; Redline, S.; Azarbarzin, A.; Sands, S.A.; Schwab, R.J.; Dunn, J.P.; Chakladar, S.; et al. SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N. Engl. J. Med.* 2024, *391*, 1193–1205, Erratum in *N. Engl. J. Med.* 2024, *391*, 1464. https://doi.org/10.1056/NEJMx240005.. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
29. Packer, M.; Zile, M.R.; Kramer, C.M.; Baum, S.J.; Litwin, S.E.; Menon, V.; Ge, J.; Weerakkody, G.J.; Ou, Y.; Bunck, M.C.; et al. SUMMIT Trial Study Group. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. *N. Engl. J. Med.* 2025, *392*, 427–437. [Google Scholar] [CrossRef] [PubMed]
30. Parlițeanu, O.; Nemes, R.; Balteanu, M.A.; Radu, D.; Gherlan, G. Pathophysiological mechanisms and benefits of SGLT-2 inhibitors in a patient with cerebral artery aneurysm: A case report. *Exp. Ther. Med.* 2025, *29*, 112. [Google Scholar] [CrossRef]
31. Dal Canto, E.; Ceriello, A.; Rydén, L.; Ferrini, M.; Hansen, T.B.; Schnell, O.; Standl, E.; Beulens, J.W. Diabetes as a cardiovascular risk factor: An overview of global trends of macro and micro vascular complications. *Eur. J. Prev. Cardiol.* 2019, *26* (Suppl. S2), 25–32. [Google Scholar] [CrossRef] [PubMed]
32. Nica, A.E.; Rusu, E.; Dobjanschi, C.G.; Rusu, F.; Parliteanu, O.A.; Sivu, C.; Radulian, G. The Importance of Evaluating Sudomotor Function in the Diagnosis of Cardiac Autonomic Neuropathy. *Cureus* 2024, *16*, e57226. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
33. Whitaker, M.E.; Nair, V.; Sinari, S.; Dherange, P.A.; Natarajan, B.; Trutter, L.; Brittain, E.L.; Hemnes, A.R.; Austin, E.D.; Patel, K.; et al. Diabetes Mellitus Associates with

Increased Right Ventricular Afterload and Remodeling in Pulmonary Arterial Hypertension. *Am. J. Med.* 2018, *131*, e7–e702. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
34. Available online: https://www.who.int/health-topics/diabetes#tab=tab_1 (accessed on 20 May 2025).
35. Available online: https://www.who.int/news/item/01-03-2024-one-in-eight-people-are-now-living-with-obesity (accessed on 20 May 2025).
36. OWENS ROBERT, MSD Manual Professional Edition, 2024/08, MSD Manual, Obstructive Sleep Apnea (OSA). Available online: https://www.msdmanuals.com/professional/pulmonary-disorders/sleep-apnea/obstructive-sleep-apnea-osa (accessed on 20 May 2025).
37. Parlițeanu, O.-A.; Bălteanu, M.-A.; Zaharia, D.C.; Constantinescu, T.; Cristea, A.M.; Dumitrache-Rujinscki, Ș.; Nica, A.E.; Voineag, C.; Alexe, O.S.; Tabacu, E.; et al. The Impact of SARS-CoV-2 Infection on Glucose Homeostasis in Hospitalized Patients with Pulmonary Impairment. *Diagnostics* 2025, *15*, 554. [Google Scholar] [CrossRef] [PubMed]
38. Mahler, B.; Parliteanu, O.A.; Alexe, O.; Rîșcă Popazu, C.; Ene, C.E.; Timar, B.; Constantinescu, T. Mucormycosis in a Patient with Severe COVID-19 Disease—The First Case Report in Romania and a Literature Review. *Medicina* 2023, *59*, 555.

2. Teza/tezele de doctorat:

T1. ……
T2. ……
……

3. Brevete de invenţie şi alte titluri de proprietate intelectuală (dacă este cazul):

B1. ……
B2. ……
……

4. Cărţi de specialitate şi capitole în cărţi de specialitate (cu referinţe bibliografice complete):

C1. ……
C2. ……
……

5. Articole/studii *in extenso* în reviste de specialitate (cu referinţe bibliografice complete):

A1. ……
A2. ……
……

6. Publicaţii *in extenso*, apărute în lucrări ale principalelor conferinţe internaţionale de specialitate (cu referinţe bibliografice complete):

P1. ……
P2. ……
……

7. Proiecte de cercetare/dezvoltare pe bază de contract/grant (director grant/membru în echipă):

G1. ……
G2. ……
……

8. Alte lucrări şi contribuţii ştiinţifice:

L1. **PARTICIPARE LA : INTERNATIONAL CONFERENCE**
November 20 - 22, 2025
EDUCATION AND CREATIVITY FOR A KNOWLEDGE BASED SOCIETY
(19TH EDITION). BUCURESTI
Daniel RADU, Roxana Maria NEMEȘ, Oana-Andreea PARLITEANU, Alexandra Floriana NEMEȘ,

INSULIN RESISTANCE AND RIGHTVENTRICULAR DYSFUNCTION: PATHOPHYSIOLOGICAL MECHANISMS AND IMPLICATIONS FOR PULMONARY FUNCTION – A CRITICAL SYNTHESIS OF RECENT EVIDENCE.

L2.PARTICIPARE LA: CONFERINȚA CU PARTICIPARE INTERNAȚIONALĂ A FACULTĂȚII DE MEDICINĂ A UNIVERSITĂȚII TITU MAIORESCU DIN BUCUREȘTI EDIȚIA A VIII-A 16 - 18 MAI 2025 "ABORDĂRI INOVATOARE TRANSDISCIPLINARE IN MEDICINA MODERNA" Dinamicile fiziopatologice ale stopului cardio-respirator și relevanța ferestrei terapeutice în optimizarea prognosticului. Pathophysiological Dynamics of Cardiac Arrest and the Relevance of the Therapeutic Window in Prognostic Optimization. Radu Daniel, Parliteanu Oana, Nemes Roxana Maria.

9. Traduceri de lucrări ştiinţifice:

TR1. ……..
TR2. ……..
……. …….

Declar pe proprie răspundere că datele prezentate sunt în conformitate cu realitatea

Data : 19.12.2025 (prenume, nume, semnătura)

DANIEL RADU